论文部分内容阅读
目的 :探讨α 干扰素联合大剂量胸腺肽治疗慢性乙型肝炎的疗效。方法 :采用α 干扰素或联合应用大剂量胸腺肽治疗慢性乙型肝炎 ,检测前后患者HBV血清学指标肝功能变化等。结果 :表明在治疗结束时及结束后在抗HBV方面α 干扰素联合应用大剂量胸腺肽组HBV DNA、HBeAg阴转率显著高于干扰素及对照组 (P <0 .0 1)。治疗结束后 3个月HBV DNA、HBeAg阴转率都高于治疗结束时 ,且联合用药组疗效显著高于干扰素单用组 (P <0 .0 1)。结论 :两药联合应用治疗慢性乙型肝炎的近期及远期疗效均明显优于干扰素组。
Objective: To investigate the efficacy of interferon α combined with high-dose thymosin in the treatment of chronic hepatitis B. Methods: Interferon-α or combined with high-dose thymosin in the treatment of chronic hepatitis B, HBV serological tests before and after the changes in liver function. Results: The HBV DNA and HBeAg negative rates of interferon combined with high dose of thymosin in the anti-HBV group were significantly higher than that of interferon and control group (P <0.01) at the end of treatment and after the treatment. The HBV DNA and HBeAg negative conversion rates at 3 months after the end of treatment were all higher than those at the end of treatment, and the combination therapy group was significantly higher than the interferon group alone (P <0.01). Conclusion: The combination of the two drugs in the treatment of chronic hepatitis B has better short-term and long-term curative effects than the interferon group.